We read with interest Dr Duggal's letter on the combined use of atypical antipsychotics (AAs) and cognitivebehavioural therapy (CBT) in schizophrenia (1) . Dr Duggal reports that his patient showed a reduction of 54% in symptom severity as indexed by the Positive and Negative Syndrome Scale (PANSS). His baseline score when unmedicated was 129 and varied from 83 to 102 with medication; when medication was combined with CBT, his PANSS score was 59.
Dr Duggal's finding is consistent with, and adds to, the existing literature on the combined use of second-generation antipsychotics (SGAs) and CBT. Our Symptom-Specific Group Treatment Program (conducted at Bronx Psychiatric Center) was designed to match the 5 symptom dimensions of the PANSS: positive, negative, activation, dysphoria, and autistic preoccupation (2) . We found that patients attending symptom-specific groups in addition to receiving standard medications showed an additional 22% decrease in symptom severity when compared with a group of patients receiving standard medications alone (3) .
We question only Dr Duggal's speculation that "AAs potentiate CBT." CBT has been found to be useful in patients who receive standard neuroleptics, including those in our sample, as well as in patients receiving SGAs. Further, it may well be that SGAs and CBT do not potentiate one another but that their effects are additive. The 2 treatment modalities may be targeting different facets of schizophrenia. For example, CBT may teach or remediate coping skills, cognitive functions, and social adeptness impaired during acute psychosis; standard neuroleptics target positive symptoms, and SGAs target positive, negative, activation, dysphoria, and autistic preoccupation symptoms.
More work is needed to better understand whether the interaction between antipsychotics and CBT is additive or synergistic, as well as how CBT works with different antipsychotics.
Anne-Marie Shelley, PhD Lewis A Opler, MD, PhD Joseph Battaglia, MD Jeffrey Lucey, MD Mount Vernon, New York

Reply: The Combined Use of Atypical Antipsychotics and Cognitive-Behavioural Therapy in Schizophrenia
Dear Editor: I thank Dr Opler and colleagues for their comments, and I agree that more work needs to be done to improve our understanding of the interplay between cognitive-behavioural therapy (CBT) and second-generation antipsychotics (SGAs). Dr Opler's definition of CBT includes teaching or remediating coping skills, cognitive functions, and social adeptness; I have broadly covered this under the domain of cognitive remediation, a part of which involves CBT. The point that SGAs may potentiate the effect of CBT in schizophrenia derives from reports of other medications interfering with CBT (for example, benzodiazepines have a detrimental effect in anxiety disorders, because they impair memory function). Thus if SGAs improve new learning, which in part is the cognitive mechanism involved in CBT, it may be reasonable to hypothesize that SGAs potentiate the effect of CBT. I endorse Dr Opler's view that CBT and SGAs may target different symptom profiles, but CBT in schizophrenia has been used for positive symptoms, including delusions, somatic passivity, and hallucinations.
